 |
 |
 |
|
On-Treatment HCV RNA as a Predictor of Virologic Response in the Ledipasvir/Sofosbuvir Phase 3 Program for HCV Genotype 1 Infection: Analysis of the ION-1, ION-2, and ION-3 Studies
|
|
|
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
Tania M. Welzel,1* Eva Herrmann,1* Patrick Marcellin,2 Nezam H. Afdhal,3 Kris V. Kowdley,4 Luisa M. Stamm,5 Yanni Zhu,5 Phillip S. Pang,5 John G. McHutchison,5 Stefan Zeuzem1
1Goethe University Hospital, Frankfurt, Germany; 2Beaujon Hospital, Paris, France; 3Beth Israel Deaconess Medical Center, Boston, MA; 4Virginia Mason Medical Center, Seattle, WA; 5Gilead Sciences, Inc., Foster City, CA






|
|
|
 |
 |
|
|